In this article, we discuss the 5 best German stocks to buy now. If you want to read about some more best German stocks, go directly to the 11 Best German Stocks to Buy Now.
5. MorphoSys AG (NASDAQ:MOR)
Number of Hedge Fund Holders: 5
MorphoSys AG (NASDAQ:MOR) is a commercial-stage biopharmaceutical company that engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. On November 16, MorphoSys posted earnings for the third quarter of 2022, reporting losses per share of €3.60. The revenue over the period was €95.8 million, up 132.5% compared to the revenue over the same period last year.
On November 18, JMP Securities analyst Jason Butler maintained an Outperform rating on MorphoSys AG (NASDAQ:MOR) stock and lowered the price target to $15 from $32, noting that despite the recent disappointment on partnered programs, the company continues to execute well on proprietary pipeline opportunities with continued enrollment in late-stage trials for pelabresib.
At the end of the third quarter of 2022, 5 hedge funds in the database of Insider Monkey held stakes worth $10 million in MorphoSys AG (NASDAQ:MOR), compared to 2 in the previous quarter worth $8.6 million.
4. Fresenius Medical Care AG & Co. KGaA (NYSE:FMS)
Number of Hedge Fund Holders: 13
Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) provides dialysis care and related dialysis care services in Germany, North America, and internationally. On August 30, Fresenius announced that it had been awarded a contract from the US Department of Veterans Affairs to provide dialysis services to military veterans. According to the contract, Fresenius will help treat more than 35 thousand military veterans getting dialysis from the VA.
On November 9, Credit Suisse analyst Christoph Gretler maintained a Neutral rating on Fresenius Medical Care AG & Co. (NYSE:FMS) stock and lowered the price target to EUR 32 from EUR 37.
Among the hedge funds being tracked by Insider Monkey, New York-based investment firm Pzena Investment Management is a leading shareholder in Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) with 13 million shares worth more than $184 million.
In its Q3 2022 investor letter, Artisan Partners, an asset management firm, highlighted a few stocks and Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) was one of them. Here is what the fund said:
“We exited our position in Fresenius Medical Care AG & Co. KGaA (NYSE:FMS), a vertically integrated provider of dialysis equipment and services. The company has experienced headwinds related to the pandemic, most notably due to the higher mortality rates found among dialysis patients. We anticipated the business would recover post-COVID and benefit from the secular growth of its end markets; however, the company has also suffered from cost inflation pressures and reimbursement challenges. Based on these factors, we chose to sell our remaining shares in favor of better opportunities.”
